Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8485150 | 0.90 | L3MBTL1 (0.41) | L3MBTL1GAAOPRK1NR1H2NR1H3 | |
| SCHEMBL8668077 | 0.83 | OPRK1 (0.32) | OPRK1 | |
| SCHEMBL8714746 | 0.82 | CHRM1 (0.38) | GAA | |
| SCHEMBL8503795 | 0.81 | OPRK1 (0.31) | OPRK1 | |
| SCHEMBL8485124 | 0.80 | OPRK1 (0.33) | OPRK1 | |
| SCHEMBL8669690 | 0.78 | UTS2R (0.39) | GAA | |
| SCHEMBL8480408 | 0.77 | TMEM97 (0.38) | TMEM97HTR2ASIGMAR1L3MBTL1HTR2B | |
| SCHEMBL8502242 | 0.76 | NPSR1 (0.35) | TMEM97SIGMAR1GAA | |
| SCHEMBL8664326 | 0.74 | MTR (0.35) | — | |
| SCHEMBL8485599 | 0.74 | MTR (0.38) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |